Dr. Samir Kapadia

About Samir Kapadia

Education:

• Graduated with an MBBS (Bachelor of Medicine, Bachelor of Surgery) from Smt. NHL Municipal Medical College, Gujarat, India, in 1990.

Experience:

• Completed internship and residency in internal medicine at Baylor College of Medicine, Houston, earning the title of Outstanding Resident in 1993.
• Undertook fellowships in cardiology (1998) and interventional cardiology (2000) at Cleveland Clinic, Cleveland, where he was also the Chief Interventional Fellow.
• Worked as an interventional cardiologist at the VA Puget Sound Health Care System, Seattle, with an academic appointment at the University of Washington (2000–2003).
• Joined Cleveland Clinic as an interventional cardiologist in 2003, later becoming the Director of the Sones Cardiac Catheterization Laboratories in 2009 and Section Head of Invasive and Interventional Cardiology in 2014.
• Appointed Chairman of the Department of Cardiovascular Medicine at Cleveland Clinic in 2019.

Affiliated Hospitals

Cleveland Clinic

The Cleveland Clinic Foundation

Clinical Trials Samir Kapadia is currently running

Cardiac MRI

for Mitral Regurgitation

The goal of the current research is to develop personalized risk prediction for functional mitral regurgitation (FMR) patients through explainable unsupervised phenomapping enriched with advanced cardiac magnetic resonance (CMR) imaging biomarkers, and to determine the CMR predictors of reverse remodeling following modern therapies for FMR. The prospective study entails aiming to recruit 360 adult patients (ages \>18 years) with EF 10-50% and FMR RF\> 20%, who are clinically referred for CMR evaluation. Patients who enroll in our study will be referred for optimization of mGDMT and will undergo follow-up CMR studies at 6months. NICM patients who are fully medically optimized with significant FMR at the time of the baseline CMR and are referred for Mitraclip treatment will undergo follow-up CMR 6 months from Mitraclip intervention. NICM patients referred for mGDMT optimization, but have persistent or progressive FMR at the time of 6 month follow-up CMR and referred for Mitraclip therapy, will undergo a 2nd follow-up CMR 6 months from Mitraclip therapy.

Recruiting

1 award

N/A

1 criteria

Cephea Valve System

for Mitral Regurgitation

This trial is testing a new device called the Cephea Mitral Valve System that can fix or replace a damaged heart valve using a thin tube. It aims to help patients with mitral valve disease who need a less invasive treatment than open-heart surgery. The Cephea Mitral Valve System is a new technology developed by Cephea Valve Technologies, aiming to treat severe mitral regurgitation through a less invasive approach.

Recruiting

1 award

N/A

More about Samir Kapadia

Clinical Trial Related

7 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 5 Active Clinical Trials

Other Doctors you might be interested in

Frequently asked questions